These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
971 related articles for article (PubMed ID: 31801334)
1. Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D). Das AK; Kalra S; Tiwaskar M; Bajaj S; Seshadri K; Chowdhury S; Sahay R; Indurkar S; Unnikrishnan AG; Phadke U; Pareek A; Purkait I J Assoc Physicians India; 2019 Dec; 67(12):65-74. PubMed ID: 31801334 [TBL] [Abstract][Full Text] [Related]
2. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395 [TBL] [Abstract][Full Text] [Related]
3. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study). Gupta A Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476 [TBL] [Abstract][Full Text] [Related]
4. Effects of Hydroxychloroquine on Progression of Diabetic Retinopathy in Subjects with Rheumatoid Arthritis and Type 2 Diabetes Mellitus. Baidya A Curr Diabetes Rev; 2022; 18(9):e180122200322. PubMed ID: 35040415 [TBL] [Abstract][Full Text] [Related]
5. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Krentz AJ; Bailey CJ Drugs; 2005; 65(3):385-411. PubMed ID: 15669880 [TBL] [Abstract][Full Text] [Related]
6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
7. Expression of Circulating MicroRNAs and Myokines and Interactions with Serum Osteopontin in Type 2 Diabetic Patients with Moderate and Poor Glycemic Control: A Biochemical and Molecular Study. Al-Rawaf HA; Alghadir AH; Gabr SA Biomed Res Int; 2021; 2021():7453000. PubMed ID: 34917685 [TBL] [Abstract][Full Text] [Related]
8. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. Penn SK; Kao AH; Schott LL; Elliott JR; Toledo FG; Kuller L; Manzi S; Wasko MC J Rheumatol; 2010 Jun; 37(6):1136-42. PubMed ID: 20436082 [TBL] [Abstract][Full Text] [Related]
9. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Wasko MC; McClure CK; Kelsey SF; Huber K; Orchard T; Toledo FG Diabetologia; 2015 Oct; 58(10):2336-43. PubMed ID: 26197707 [TBL] [Abstract][Full Text] [Related]
10. Diabetes and branched-chain amino acids: What is the link? Bloomgarden Z J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529 [TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach. Mikkelsen RR; Hundahl MP; Torp CK; Rodríguez-Carrio J; Kjolby M; Bruun JM; Kragstrup TW Eur J Pharmacol; 2022 Jun; 925():174998. PubMed ID: 35533739 [TBL] [Abstract][Full Text] [Related]
12. Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic. Infante M; Ricordi C; Fabbri A J Diabetes; 2020 Sep; 12(9):659-667. PubMed ID: 32401405 [TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Esser N; Paquot N; Scheen AJ Expert Opin Investig Drugs; 2015 Mar; 24(3):283-307. PubMed ID: 25345753 [TBL] [Abstract][Full Text] [Related]
14. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Everett BM; Donath MY; Pradhan AD; Thuren T; Pais P; Nicolau JC; Glynn RJ; Libby P; Ridker PM J Am Coll Cardiol; 2018 May; 71(21):2392-2401. PubMed ID: 29544870 [TBL] [Abstract][Full Text] [Related]
15. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study. Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050 [TBL] [Abstract][Full Text] [Related]
16. Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents. Infante M; Padilla N; Alejandro R; Caprio M; Della-Morte D; Fabbri A; Ricordi C Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35629988 [TBL] [Abstract][Full Text] [Related]
17. SGLT2i as a First-line Antihyperglycemic in the Management of Type 2 Diabetes in the Context of Indians: A Systematic Review and Consensus. Singh AK; Misra A; Das AK; Behl A; Srivastava A; Paneerselvam A; Chidambaram B; Saboo B; Sethi B; Makkar BM; Bantwal G; Thacker H; Panda J; Kesavadev J; Seshadri KG; Tiwaskar M; Shunmugavelu M; Sahay R; Das S; Agarwal S; Shaikh S; Sharma SK; Gupta S; Bhattacharyya S; Mohan V; Gunupati VK J Assoc Physicians India; 2023 Dec; 71(12):62-74. PubMed ID: 38736056 [TBL] [Abstract][Full Text] [Related]